CD40 and B chronic lymphocytic leukemia cell response to fludarabine:: The influence of NF-κB/Rel transcription factors on chemotherapy-induced apoptosis

被引:11
作者
Romano, MF [1 ]
Lamberti, A [1 ]
Turco, MC [1 ]
Venuta, S [1 ]
机构
[1] Dept Biochem, Naples, Italy
关键词
apoptosis; CD40; NF-kappa B/Rel;
D O I
10.3109/10428190009148846
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
The levels of tumour necrosis factor receptor (TNF-R) superfamily members can be altered in lymphoid leukemias, indicating a possible role of such molecules in the biology of these neoplasias. In B chronic lymphocytic leukemia cells, the CD40/CD40L system has been shown to be effective in inhibiting the apoptotic response to fludarabine. The modulation of apoptosis relied on the CD40- induced activity of NF-kappa B/Rel transcription factors. The anti- apoptotic effect of CD40 was abolished using a phosphorothioate kappa B decoy oligodeoxynucleotide. These findings illustrate an example of the biological activity of TNF-R- like molecules in leukemias. They also show the influence of NF-kappa B/Rel activity on leukemic cell response to apoptogenic agents.
引用
收藏
页码:255 / 262
页数:8
相关论文
共 53 条
[1]   Prolonged phenotypic, functional, and molecular change in group I Burkitt lymphoma cells on short-term exposure to CD40 ligand [J].
Baker, MP ;
Eliopoulos, AG ;
Young, LS ;
Armitage, RJ ;
Gregory, CD ;
Gordon, J .
BLOOD, 1998, 92 (08) :2830-2843
[2]   Multidrug resistance - A multiplex phenomenon [J].
Baldini, N .
NATURE MEDICINE, 1997, 3 (04) :378-380
[3]   The NF-kappa B and I kappa B proteins: New discoveries and insights [J].
Baldwin, AS .
ANNUAL REVIEW OF IMMUNOLOGY, 1996, 14 :649-683
[4]   THE CD40 ANTIGEN AND ITS LIGAND [J].
BANCHEREAU, J ;
BAZAN, F ;
BLANCHARD, D ;
BRIERE, F ;
GALIZZI, JP ;
VANKOOTEN, C ;
LIU, YJ ;
ROUSSET, F ;
SAELAND, S .
ANNUAL REVIEW OF IMMUNOLOGY, 1994, 12 :881-922
[5]  
Barak V, 1999, EUR J HAEMATOL, V62, P71
[6]  
Bauerle PA, 1996, CELL, V87, P13
[7]   An essential role for NF-kappa B in preventing TNF-alpha-induced cell death [J].
Beg, AA ;
Baltimore, D .
SCIENCE, 1996, 274 (5288) :782-784
[8]  
Bentires-Alj M, 1999, CANCER RES, V59, P811
[9]  
BERBERICH I, 1994, J IMMUNOL, V153, P4357
[10]   Phase I trial of an antisense oligonucleotide OL(1)p53 in hematologic malignancies [J].
Bishop, MR ;
Iversen, PL ;
Bayever, E ;
Sharp, JG ;
Greiner, TC ;
Copple, BL ;
Ruddon, R ;
Zon, G ;
Spinolo, J ;
Arneson, M ;
Armitage, JO ;
Kessinger, A .
JOURNAL OF CLINICAL ONCOLOGY, 1996, 14 (04) :1320-1326